Standard 3: Data monitoring committees

Pediatrics

Volumn 129, Issue SUPPL. 3, 2012, Pages

  Ellenberg, Susan ^a   Fernandes, Ricardo M ^b   Saloojee, Haroon ^c   Bassler, Dirk ^d   Askie, Lisa ^e   Vandermeer, Ben ^f   Offringa, Martin ^g   Van Der Tweel, Ingeborg ^h   Altman, Douglas G ⁱ   Van Der Lee, Johanna H ^j  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF ALBERTA   (Canada)

^g HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j EMMA CHILDREN S HOSPITAL   (Netherlands)

more..

Author keywords

Data monitoring committee; DMC charter; DMC reporting; Pediatric; StaR child health

Indexed keywords

CAREER; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; FINANCIAL MANAGEMENT; HUMAN; METHODOLOGY; MONITORING; MORBIDITY; MORTALITY; PEDIATRICS; PRIORITY JOURNAL; PROFESSIONAL STANDARD; RESPONSIBILITY; STATISTICAL ANALYSIS; SYMPOSIUM;

CHILD; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84861907340     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-0055F     Document Type: Conference Paper

References (27)

1. Klassen TP, Hartling L, Craig JC, Offringa M. Children are not just small adults: the urgent need for high-quality trial evidence in children. PLoS Med. 2008;5(8):e172
2. Organization, review, and administration of cooperative studies (Greenberg Report): a report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967. Control Clin Trials. 1988; 9(2):137-148
3. Shaw LW, Chalmers TC. Ethics in cooperative clinical trials. Ann N Y Acad Sci. 1970;169(2): 487-495
4. Wittes J. Behind closed doors: the data monitoring board in randomized clinical trials. Stat Med. 1993;12(5-6):419-424
5. Ellenberg SS, Fleming TR, DeMets TL. Data Monitoring Committees in Clinical Trials: A Practical Perspective. Chichester, West Sussex, United Kingdom: John Wiley & Sons, Ltd; 2002
6. Grant AM, Altman DG, Babiker AB, et al; DAMOCLES Study Group. Issues in data monitoring and interim analysis of trials. Health Technol Assess. 2005;9(7):1-238, iii-iv
7. Clemens F, Elbourne D, Darbyshire J, Pocock S; DAMOCLES Group. Data monitoring in randomized controlled trials: surveys of recent practice and policies. Clin Trials. 2005;2(1): 22-33
8. Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet. 2005;365(9460):663-670
9. Shankaran S, Laptook AR, Ehrenkranz RA, et al; National Institute of Child Health and Human Development Neonatal Research Network. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005;353(15):1574-1584
10. Smith MA, Ungerleider RS, Korn EL, Rubinstein L, Simon R. Role of independent datamonitoring committees in randomized clinical trials sponsored by the National Cancer Institute. J Clin Oncol. 1997;15(7):2736-2743
11. Cairns JA, Hallstrom A, Held P. Should all trials have a data safety and monitoring committee? Am Heart J. 2001;141(1):156-163
12. Bassler D, Montori VM, Briel M, Glasziou P, Guyatt G. Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol. 2008;61(3):241-246
13. Goodman SN. Stopping at nothing? Some dilemmas of data monitoring in clinical trials. Ann Intern Med. 2007;146(12):882-887
14. Baigent C, Harrell FE, Buyse M, Emberson JR, Altman DG. Ensuring trial validity by data quality assurance and diversification of monitoring methods. Clin Trials. 2008;5 (1):49-55
15. DAMOCLES Study Group, NHS Health Technology Assessment Programme. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005;365(9460):711-722
16. DeMets DL, Fleming TR, Rockhold F, et al. Liability issues for data monitoring committee members. Clin Trials. 2004;1(6):525-531
17. Guidance for Clinical Trial Sponsors. Establishment and operation of clinical trial data monitoring committees. Available at: www. fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf. Accessed September 6, 2011
18. DeMets DL, Fleming TR. The independent statistician for data monitoring committees. Stat Med. 2004;23(10):1513-1517
19. Fleming TR, Ellenberg S, DeMets DL. Monitoring clinical trials: issues and controversies regarding confidentiality. Stat Med. 2002;21(19):2843-2851
20. Meinert CL. Masked monitoring in clinical trials-blind stupidity? N Engl J Med. 1998; 338(19):1381-1382
21. Fernandes RM, van der Lee JH, Offringa M. A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials. BMC Pediatr. 2009;9:77
22. Moher D, Hopewell S, Schulz KF, et al; Consolidated Standards of Reporting Trials Group. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63(8):e1-e37
23. Ankum WM, Reitsma JB, Offringa M; Hippocratic role of Data Monitoring Committees. IVF with preimplantation genetic screening, a promising new treatment with unexpectedly negative health outcomes: the Hippocratic role of Data Monitoring Committees. Hum Reprod. 2008;23(1):1-3
24. DeMets DL, Furberg CD, Friedman LM. Data Monitoring in Clinical Trials: A Case Studies Approach. New York, NY: Springer; 2006
25. Fleming TR, Neaton JD, Goldman A, et al; Terry Beirn Community Programs for Clinical Research on AIDS. Insights from monitoring the CPCRA didanosine/zalcitabine trial. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(suppl 2):S9-S18
26. The Coronary Drug Project Research Group. Practical aspects of decision making in clinical trials: the coronary drug project as a case study. Control Clin Trials. 1981;1(4): 363-376
27. Wheatley K, Clayton D. Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization. Control Clin Trials. 2003;24(1):66-70